

Balaxi Pharmaceuticals Limited

May 09, 2023

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Conversion of Warrants and Allotment of Equity Shares

Dear Sir/Madam,

This is in reference to our letter dated October 11, 2022, regarding allotment of Convertible Warrants on Preferential Basis and pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby inform you that seven (7) of the convertible warrant holders to whom the warrants were allotted on October 11, 2022, have exercised their right of conversion and applied for conversion of the warrants into equity shares. Consequently, the Board of Directors vide circular resolution passed today i.e. May 09, 2023 have approved the allotment of 48,950 (Forty Eight Thousand Nine Hundred and Fifty) Equity Shares at an issue price of Rs. 451/- (Rupees Four Hundred and Fifty-One only) each i.e., of the face value of Rs. 10/- each and at a premium of Rs. 441/- each to the warrant holders specified here-in-below:

Sno.	Name of the Allottee(s)	Category of the Allottee(s)	Sub - Category of the Allottee(s)	Total Number of Warrants held	Number of warrants applied for conversion into Equity Shares	Number of Equity Shares allotted upon conversion of warrants
1	Faisal Zubair Hawa	Public	Individual	1,10,000	27,500	27,500
2	Daizam Aggarwal	Public	Individual	20,000	6,000	6,000
3	Sharad Narayanlal Sarda	Public	Individual	5,000	5,000	5,000
4	Meenakshi Agarwal	Public	Individual	11,000	3,700	3,700
5	Ankur Gupta	Public	Individual	3,000	3,000	3,000
6	Mohamed Aamer Mohamed Afzal Mithaiwala	Public	Individual	6,250	2,750	2,750
7	Saurabh Dixit	Public	Individual	6,000	1,000	1,000
Total				1,61,250	48,950	48,950

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Balaxi Pharmaceuticals Limited

The allotment has been made on receipt of the balance exercise price payable of Rs. 338.25/- per warrant (being an amount equivalent to 75% of the warrant exercise price of Rs. 451/- per warrant), aggregating to Rs. 1,65,57,337.50/- (One Crore Sixty-Five Lakhs Fifty Seven Thousand Three Hundred and Thirty Seven Rupees and Fifty Paise only).

Consequent to the allotment of above-mentioned equity shares, the paid-up capital of the Company has increased to Rs. 10,23,02,000/- (Rupees Ten Crores Twenty-Three Lakhs Two Thousand only) comprising of 1,02,30,200 (One Crore Two Lakhs Thirty Thousand Two Hundred) Equity Shares of face value Rs. 10/- (Rupees Ten only) each.

This intimation will also be available on the Company's Website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

Udayan Shukla

(Company Secretary and Compliance Officer)

Membership No.: F11744

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in